Wren Therapeutics Ltd

WaveBreak Therapeutics Ltd. is a privately held biopharmaceutical company based in Cambridge, Massachusetts. With a team of 14 employees, the company has generated $2.5 million in revenue. WaveBreak specializes in developing innovative therapies for neurodegenerative diseases. Their primary focus is on targeting fleeting protein intermediates known as oligomers, which are believed to play a crucial role in the progression of diseases such as Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS. The company's unique drug discovery platform enables them to interrupt the molecular mechanisms responsible for the formation of these harmful oligomers. By leveraging small-molecule therapeutics, WaveBreak aims to halt the disease pathways at their source, offering new hope for patients with these debilitating conditions. For more information about WaveBreak Therapeutics Ltd. and their groundbreaking research, please visit their website at wavebreaktx.com.